Celiac Disease Diagnosis and Management

Clinical Presentation and Diagnosis

The American Gastroenterological Association suggests that celiac disease frequently occurs without gastrointestinal symptoms, representing a substantial proportion of cases, often presenting with only extraintestinal manifestations or remaining completely asymptomatic 1, 2, 3
Silent celiac disease is diagnosed through screening of high-risk groups despite complete absence of symptoms, and this presentation is now recognized as at least as common as classic gastrointestinal presentations 3
The disease affects approximately 1% of the population, but only 24% of those with celiac disease are diagnosed, creating a "celiac iceberg" of undiagnosed cases—many of whom lack typical GI symptoms 1, 3
Variation in clinical presentation ranges from none (asymptomatic) to a broad spectrum of symptoms, with non-specific or extraintestinal symptoms being extremely common and often leading to delayed diagnosis 1, 3

The American College of Gastroenterology recommends screening in asymptomatic individuals from high-risk groups, as these patients are more likely to present without classical symptoms 1, 2
First-degree relatives of people with celiac disease (7.5% risk) should be screened 2, 3
Patients with type 1 diabetes (5-10% prevalence) should be screened 2, 3
Individuals with autoimmune thyroid disease should be screened 2, 3
Patients with Down syndrome or Turner syndrome should be screened 2, 3
Those with autoimmune liver disease should be screened 2

IgA tissue transglutaminase (tTG-IgA) with total IgA level remains the first-line test, even in asymptomatic patients or those with only extraintestinal symptoms (sensitivity 90.7%, specificity 87.4% in adults) 1, 4
IgA endomysial antibodies (EMA) serve as confirmatory testing with excellent specificity (99.6% in adults) 1, 4
Total IgA must be measured simultaneously, as IgA deficiency occurs 10-15 times more frequently in celiac patients and causes false-negative results 5, 4

Upper endoscopy with duodenal biopsy remains the gold standard for diagnosis, even in asymptomatic patients with positive serology 4, 6
Obtain at least 6 biopsy specimens (1-2 from duodenal bulb and at least 4 from second part of duodenum) to avoid sampling error 4, 6
The patient must be consuming adequate gluten (at least 10g daily for 6-8 weeks) before testing, as gluten-free or gluten-reduced diets yield false-negative results 6
Left undiagnosed and untreated, celiac disease—even when asymptomatic—leads to higher risk of complications including osteoporosis, infertility, and small bowel cancer 1

First-degree relatives of celiac disease patients have a ~10% prevalence of asymptomatic celiac disease, many detected only through screening without symptoms, according to the American Gastroenterological Association 7
Patients with iron deficiency anemia without GI symptoms have a 2-5% prevalence of celiac disease by serology and 3-9% by endoscopy, lacking gastrointestinal complaints, as reported by the American Gastroenterological Association 7
Adults and children with type 1 diabetes have a 2-5% and 3-8% prevalence of asymptomatic celiac disease, respectively, frequently asymptomatic, according to the American Gastroenterological Association 7
Patients with osteoporosis have a 1.5-3% prevalence of asymptomatic celiac disease, typically without GI symptoms, as noted by the American Gastroenterological Association 7
Individuals with autoimmune thyroid disease have a 3% pooled prevalence of asymptomatic celiac disease, often asymptomatic for celiac disease, according to the American Gastroenterological Association 7
Patients with Down syndrome have a 5.5% confirmed prevalence of asymptomatic celiac disease by biopsy, frequently detected only through screening, as reported by the American Gastroenterological Association 7
Individuals with Turner syndrome have a 6.3% pooled prevalence of asymptomatic celiac disease, often without GI manifestations, according to the American Gastroenterological Association 7

The British Society of Gastroenterology notes that the proportion of newly diagnosed patients with malabsorptive symptoms has decreased over time, while non-classical and asymptomatic presentations have gained prominence, indicating a shift away from classic GI presentations 8

The American Gastroenterological Association explicitly identifies Sjögren's syndrome as a condition where celiac disease testing should be selectively considered during medical evaluation, particularly when symptoms compatible with celiac disease are present 9, 10, 11.
The increased prevalence of Sjögren's syndrome in celiac disease patients is explained by shared HLA susceptibility genes (DQ2 and DQ8) 12, 9.
The American Gastroenterological Association position statement recommends selective testing for celiac disease in patients with type 1 diabetes mellitus, especially when symptoms suggesting celiac disease are present 9, 10, 11.
The American Gastroenterological Association explicitly recommends testing for celiac disease in patients with primary biliary cirrhosis, with prevalence ranging from 0% to 6.0% 12, 9.

Mandatory screening for celiac disease is recommended in primary biliary cholangitis patients with unexplained symptoms and type 1 diabetes patients, especially with any GI symptoms, unexplained anemia, or growth issues 9, 10, 11.
Selective screening for celiac disease is recommended in Sjögren's syndrome patients with fatigue, diarrhea, weight loss, or anemia 10.
Selective screening for celiac disease is also recommended in patients with unexplained iron deficiency, osteoporosis, or elevated transaminases 12.

In patients with advanced liver disease, tTG antibodies may be falsely elevated, particularly with older guinea pig-based assays 12, 9.
The shared HLA-DQ2/DQ8 genetic background explains clustering of these autoimmune conditions in the same patients 12.